Portal de Periódicos da CAPES

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

2022; Multidisciplinary Digital Publishing Institute; Volume: 14; Issue: 22 Linguagem: Inglês

10.3390/cancers14225530

2072-6694

Chiara Cattaneo, Jon Salmanton‐García, Francesco Marchesi, Shaimaa El‐Ashwah, Federico Itri, Barbora Weinbergerová, María Gomes da Silva, Michelina Dargenio, Julio Dávila, Sonia Martín‐Pérez, Francesca Farina, Jaap A. van Doesum, Toni Valković, Caroline Besson, Christian Bjørn Poulsen, Alberto López‐García, Павел Зак, Martin Schönlein, Klára Piukovics, Ozren Jakšić, Alba Cabirta, Natasha Ali, Uluhan Sili, Nicola Fracchiolla, Giulia Dragonetti, Tatjana Adžić‐Vukičević, Monia Marchetti, Marina Machado, Andreas Glenthøj, Olimpia Finizio, Fatih Demırkan, Ola Blennow, Maria Chiara Tisi, Ali S. Omrani, Milan Navrátil, Zdeněk Ráčil, Jan Novák, Gabriele Magliano, Moraima Jiménez, Carolina García‐Vidal, Nurettin Erben, Maria Ilaria Del Principe, Caterina Buquicchio, Rui Bergantim, Josip Batinić, Murtadha Al‐Khabori, Luisa Verga, Tomáš Szotkowski, Michail Samarkos, Irati Ormazabal‐Vélez, Stef Meers, Johan Maertens, László Imre Pinczés, Martin Hoenigl, Ľuboš Drgoňa, Annarosa Cuccaro, Yavuz M. Bilgin, Avinash Aujayeb, Laman Rahimli, Stefanie Gräfe, Mariarita Sciumè, Miloš Mladenović, Gökçe Melis Çolak, Maria Vittoria Sacchi, Anna Nordlander, Caroline Berg Venemyr, Michaela Hanáková, Nicole García‐Poutón, Ziad Emarah, Giovanni Paolo Maria Zambrotta, Raquel Nunes Rodrigues, Raúl Córdoba, Gustavo‐Adolfo Méndez, Monika Biernat, Oliver A. Cornely, Livio Pagano,

Lymphadenopathy Diagnosis and Analysis

Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.